

## **EC** Certificate

Directive 98/79/EC Annex IV, excluding Sections 4 and 6
Full Quality Assurance System
In Vitro Diagnostic Medical Devices

Registration No.:

HL 60139396 0001

Report No.:

21220990 009

Manufacturer:

Fujirebio Diagnostics AB Elof Lindälvs gata 13 SE-414 58 Göteborg

Sweden

Thomas Stjernkvist, M. Sc. Regulatory Affairs & Quality Systems Manager

Fujirebio Diagnostics AB Elof Lindälvs gata 13 SE-414 58 Göteborg, Sweden

Phone: +46 (0) 31 304 90 00 www.fdab.com - info@fdab.com

Products:

Reagents and reagent products for determining

the tumoral marker PSA

Replaces Certificate, Registration No.: HL 60096837 0001

**Expiry Date:** 

2024-05-24

The Notified Body hereby declares that the requirements of Annex IV, excluding section 4 and 6 of the directive 98/79/EC have been met for the listed products. The above named manufacturer has established and applies a quality assurance system, which is subject to periodic surveillance, defined by Annex IV, section 5 of the aforementioned directive. For placing on the market of List A devices covered by this certificate an EC design-examination certificate according to Annex IV, section 4 and a LGA Programment of manufactured products according to section 6 is required.

**Effective Date:** 

2019-10-16

Date:

2019-07-18

Notified Body

oipl.-Ing Sen Hoffmann

ÜVRheinla

TÜV Rheinland LGA Products GmbH - Tillystraße 2 - 90431 Nürnberg
TÜV Rheinland LGA Products GmbH is a Notified Body according to Directive 98/79/EC
concerning in vitro diagnostic medical devices with the identification number 0197.





Fujirebio Diagnostics AB Elof Lindälvs gata 13 Box 121 32 SE-414 58 Göteborg Sweden

To whom it concern

## FREE SALES CERTIFICATE

It is hereby certified that Fujirebio Diagnostics AB, Elof Lindälvs gata 13, Box 121 32, SE-414 58 Göteborg, Sweden, is the manufacturer of the product/products listed in the attached product list.

The Swedish Medical Products Agency certifies that these devices are not under restrictions given by the Swedish Medical Product Agency and may be exported without restrictions. The devices are freely marketed in Sweden.

This certificate is valid until May 25, 2022

On behalf of the Swedish Medical Products Agency

Sinikka Gustafsson
Senior Administrative Officer



| Product Name                 | Article Number          |
|------------------------------|-------------------------|
| AMH Control                  | 660-20 / 17350066140579 |
| CanAg AFP EIA                | 600-10 / 17350066140371 |
| CanAg CA125 EIA              | 400-10 / 17350066140241 |
| CanAg CA15-3 EIA             | 200-10 / 17350066140081 |
| CanAg CA19-9 EIA             | 120-10 / 17350066140050 |
| CanAg CA242 EIA              | 101-10 / 17350066140012 |
| CanAg CEA EIA                | 401-10 / 17350066140289 |
| CanAg Free PSA EIA           | 350-10 / 17350066140203 |
| CanAg NSE EIA                | 420-10 / 17350066140340 |
| CanAg ProGRP EIA             | 220-10 / 17350066140159 |
| CanAg PSA EIA                | 340-10 / 17350066140173 |
| CanAg S100 EIA               | 708-10 / 17350066140388 |
| CanAg SCC EIA                | 800-10 / 17350066140401 |
| CanChek Tumor Marker Control | 107-20 / 17350066140036 |
| CYFRA 21-1 EIA               | 211-10 / 17350066140135 |
| HE4 EIA                      | 404-10 / 17350066140302 |
| Lung Marker Control          | 240-20 / 17350066140531 |
| Mesothelin Control           | 360-20 / 17350066140524 |
| Tumor Marker Control         | 108-20 / 17350066140043 |

## **DECLARATION OF CONFORMITY**

We, Fujirebio Diagnostics AB hereby declare that the products listed below comply with the In Vitro Medical Device Directive 98/79/EC and its relevant transposition into the national laws of the member states in which the devices are intended to be placed on the market.

| Product name         | Prod No  | Product grouping         |
|----------------------|----------|--------------------------|
| CanAg AFP EIA        | 600-10*  | Common/Other IVD product |
| CanAg CA125 EIA      | 400-10*  | Common/Other IVD product |
| CanAg CA15-3 EIA     | 200-10*  | Common/Other IVD product |
| CanAg CA19-9 EIA     | 120-10*  | Common/Other IVD product |
| CanAg CA242 EIA      | 101-10*  | Common/Other IVD product |
| CanAg CEA EIA        | 401-10*  | Common/Other IVD product |
| CanAg Free PSA EIA   | 350-10** | Annex II list B          |
| CanAg NSE EIA        | 420-10*  | Common/Other IVD product |
| CanAg ProGRP EIA     | 220-10*  | Common/Other IVD product |
| CanAg PSA EIA        | 340-10** | Annex II list B          |
| CanAg S100 EIA       | 708-10*  | Common/Other IVD product |
| CanAg SCC EIA        | 800-10*  | Common/Other IVD product |
| CanChek              | 107-20*  | Common/Other IVD product |
| CYFRA 21-1 EIA       | 211-10*  | Common/Other IVD product |
| HE4 EIA              | 404-10*  | Common/Other IVD product |
| Tumor Marker Control | 108-20** | Annex II list B          |
| ProGRP Control       | 230-20*  | Common/Other IVD product |
| Mesothelin Control   | 360-20*  | Common/Other IVD product |
| Lung Marker Control  | 240-20*  | Common/Other IVD product |

<sup>\*</sup> using Annex III as the conformance assessment procedure

22 January 2021, Göteborg

**UJIREBIO** 

Fujirebio Diagnostics AB

Trong So

Thomas Stjernkvist

Regulatory affairs and Quality systems Manager

**V**FWIREBIO

Thomas Stjernkvist, M. Sc. Regulatory Affairs & Quality Systems Manager

Fuji rebio Diagnostics AB Elof Lindālva gata 13 SE-414 58 Göteborg, Sweden

Phone: + 48 (0) 31 304 90 00 www.fdab.com - info@fdab.com

<sup>\*\*</sup> using Annex IV as the conformance assessment procedure.